Sumitomo Pharma reorganizes US assets under direct control

Sumitomo Pharma (TSE:4506) announced a strategic reorganization of its U.S. assets, bringing key products ORGOVYX®, GEMTESA®, and MYFEMBREE® under its direct control. The company will acquire substantially all assets, including patent rights, related to these products from its subsidiaries, Sumitomo Pharma Switzerland GmbH (SMPS) and Urovant Sciences GmbH (USG), for approximately USD 1.8 billion. This move follows a capital restructuring in March 2025, designed to give Sumitomo Pharma greater involvement in its increasingly vital U.S. operations. The assets being transferred include intangible assets like patent rights and trademarks, raw materials, work-in-progress inventories, finished goods, and associated receivables/payables. This transaction will be offset through the loan from the Company to SMPS, among other methods. While Sumitomo Chemical remains the parent company with a 51.78% stake, Sumitomo Pharma's management emphasizes its operational independence, noting no constraints from its parent in its business activities. The company expects the US asset consolidation to have a minor impact on consolidated financial results. The deal is scheduled for completion on August 1, 2025.